Drugs / JNJ-63709178
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02715011 | Jun 2016 → Mar 2021 | acute myeloid leukemia | Janssen Research & Development, LLC | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-63709178 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02715011 ↗ |